Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9326
- Registration Number
- NCT00699998
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunderland, United Kingdom
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
- Conditions
- Diabetes MellitusCoronary Artery Disease
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT00642174
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT00385944
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2006-07-28
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 201
- Registration Number
- NCT00357968
- Locations
- 🇮🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
- Conditions
- Coronary ArteriosclerosisAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 139
- Registration Number
- NCT00356135
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- Conditions
- Coronary ArteriosclerosisAcute Coronary Syndromes
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13619
- Registration Number
- NCT00097591
- Locations
- 🇺🇸
For more information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), Global Quintiles Study Line (1-866-615-4672) or speak with your physician, Indianapolis, Indiana, United States
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Cardiovascular DiseasesHeart Diseases
- Interventions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT00059215
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Boston, Massachusetts, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.